In this issue of British Journal of Pharmacology, Thomas et al. Does CBG-DMH, a plant cannabinoid derivative, cause hypotension via a new mechanism?
Interestingly, CBD does not inhibit the hypotension caused by THC. It may be related to that caused by abnormal-cannabidiol, a CBD isomer ( Ho & Hiley, 2003), which was reported decades ago, as the effect of both compounds is inhibited by CBD.
The mechanism of the hypotensive effect is quite obscure. CBG-DMH also suppresses generation of nitric oxide and formation of tumor necrosis factor α by murine macrophages. Vasorelaxation of rat abdominal aorta by CBG-DMH was pertussis toxin-sensitive and was not inhibited by a nitric oxide synthase inhibitor or by CB1/CB2 or vanilloid receptor antagonists. (2005) reported that the nonpsychoactive dimethylheptyl homolog of cannabigerol (CBG-DMH) has hypotensive and vasorelaxant properties. At a meeting of the International Cannabinoid Research Society, Maor et al. Recently, there has been some renewed interest in the neglected plant cannabinoids. Is it possible that some of the plant cannabinoids, which are not psychoactive (and presumably do not bind to the CB1 receptor), are also active in these systems? Numerous additional receptors have been proposed ( Howlett et al., 2002). Some of the activities are CB1/CB2 cannabinoid receptor-dependent, but many are not. The best-known endocannabinoids, anandamide and 2-arachidonoyl glycerol, have been found to play a role not only in the central nervous system but also in most physiological systems that have been investigated – the immune, the cardiovascular, the reproductive, the respiratory, the skeletal systems, to name a few. The discovery of the endocannabinoid system and the plethora of activities of the endocannabinoids raise the possibility that some of the plant cannabinoids may cause related effects. Structures of some cannabinoids mentioned above.
0 kommentar(er)
